dc.contributor.author | Cakmak, Erol | |
dc.date.accessioned | 2019-07-27T12:10:23Z | |
dc.date.accessioned | 2019-07-28T09:38:28Z | |
dc.date.available | 2019-07-27T12:10:23Z | |
dc.date.available | 2019-07-28T09:38:28Z | |
dc.date.issued | 2018 | |
dc.identifier.issn | 2149-2247 | |
dc.identifier.issn | 2149-2549 | |
dc.identifier.uri | https://dx.doi.org/10.5152/etd.2018.18008 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/6347 | |
dc.description | WOS: 000432307500007 | en_US |
dc.description.abstract | Objective: This study aimed to determine the frequency of HBV reactivation and the potential predictive factors in resolved hepatitis B virus (HBV) patients [hepatitis B surface antigen (HBsAg)-negative and antibody to hepatitis B core antigen (antiHBc)-positive patients] who received rituximab-containing chemotherapy for B-cell lymphoma. Materials and Methods: A retrospective examination was performed for HBV-related markers in 106 patients before and after receiving rituximab-containing chemotherapy for CD20-positive B-cell lymphoma. Results: Of the 106 patients with CD20-positive B-cell lymphoma who received rituximab-containing chemotherapy, 98 were HBsAg negative and 8 were HBsAg positive; among the 98 patients, 64 (65.7%) were anti-HBc negative and 34 (34.7%) were anti-HBc positive. Of the 34 CD20-positive B-cell lymphoma patients with resolved HBV infection who received rituximab-containing chemotherapy, 26 (76.5%) were anti-HBsAg antibody (anti-HBs) positive and 8 (23.5%) were anti-HBs negative. Of these 8 anti-HBs-negative patients, HBV reactivation occurred in 4 (50%) patients; no HBV reactivation was observed in any of the 26 anti-HBs-positive patients. Compared with the anti-HBs-positive patients, the rate of HBV reactivation in B-cell lymphoma patients who were anti-HBs negative and had resolved HBV infection revealed a highly significant relationship (p<0.001). Conclusion: HBV reactivation occurred in 50% of the CD20-positive B-cell lymphoma anti-HBs-negative patients with resolved HBV infection who had received rituximab-containing chemotherapy and in none of the anti-HBs-positive patients. This indicates that anti-HBs negativity in the patients with resolved HBV infection is an important risk factor, and the antiviral prophylaxis should certainly be administered to such patients. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | AVES | en_US |
dc.relation.isversionof | 10.5152/etd.2018.18008 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Hepatitis B virus | en_US |
dc.subject | HBV reactivation | en_US |
dc.subject | rituximab | en_US |
dc.subject | B-cell lymphoma | en_US |
dc.title | Hepatitis B Virus Reactivation in Patients with Previously Resolved Hepatitis B Treated with Rituximab-Containing Chemotherapy for B-Cell Lymphoma | en_US |
dc.type | article | en_US |
dc.relation.journal | ERCIYES MEDICAL JOURNAL | en_US |
dc.contributor.department | [Cakmak, Erol] Cumhuriyet Univ, Fac Med, Dept Gastroenterol, Sivas, Turkey | en_US |
dc.identifier.volume | 40 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.endpage | 34 | en_US |
dc.identifier.startpage | 28 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |